{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T22:56:00Z","timestamp":1687215360628},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00115-021-01210-0","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T09:45:09Z","timestamp":1634291109000},"page":"1227-1238","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuroprotektive Therapien bei Tauopathien"],"prefix":"10.1007","volume":"92","author":[{"given":"Gesine","family":"Respondek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Krey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meret","family":"Huber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henning","family":"Pflugrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter U.","family":"H\u00f6glinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"1210_CR1","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1212\/NXI.0000000000000266","volume":"3","author":"D Apetauerova","year":"2016","unstructured":"Apetauerova\u00a0D, Scala\u00a0SA, Hamill\u00a0RW, Simon\u00a0DK, Pathak\u00a0S, Ruthazer\u00a0R, Standaert\u00a0DG, Yacoubian\u00a0TA (2016) CoQ10 in progressive supranuclear palsy. Neurol Neuroimmunol Neuroinflamm 3:e266. https:\/\/doi.org\/10.1212\/NXI.0000000000000266","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1210_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.00103","author":"BD Arbo","year":"2020","unstructured":"Arbo\u00a0BD, Andr\u00e9-Miral\u00a0C, Nasre-Nasser\u00a0RG, Schimith\u00a0LE, Santos\u00a0MG, Costa-Silva\u00a0D, Muccillo-Baisch\u00a0AL, Hort\u00a0MA (2020) Resveratrol derivatives as potential treatments for alzheimer\u2019s and parkinson\u2019s disease. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2020.00103","journal-title":"Front Aging Neurosci"},{"key":"1210_CR3","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/S1474-4422(14)70088-2","volume":"13","author":"AL Boxer","year":"2014","unstructured":"Boxer\u00a0AL, Lang\u00a0AE, Grossman\u00a0M, Knopman\u00a0DS, Miller\u00a0BL, Schneider\u00a0LS, Doody\u00a0RS, Lees\u00a0A, Golbe\u00a0LI, Williams\u00a0DR, Corvol\u00a0J\u2011C, Ludolph\u00a0A, Burn\u00a0D, Lorenzl\u00a0S, Litvan\u00a0I, Roberson\u00a0ED, H\u00f6glinger\u00a0GU, Koestler\u00a0M, Jack\u00a0CR, Van Deerlin\u00a0V, Randolph\u00a0C, Lobach\u00a0IV, Heuer\u00a0HW, Gozes\u00a0I, Parker\u00a0L, Whitaker\u00a0S, Hirman\u00a0J, Stewart\u00a0AJ, Gold\u00a0M, Morimoto\u00a0BH (2014) Davunetide in patients with progressive supranuclear palsy: a\u00a0randomised, double-blind, placebo-controlled phase 2\/3 trial. Lancet Neurol 13:676\u2013685. https:\/\/doi.org\/10.1016\/S1474-4422(14)70088-2","journal-title":"Lancet Neurol"},{"issue":"3","key":"1210_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0197-4580(95)00021-6","volume":"16","author":"H Braak","year":"1995","unstructured":"Braak\u00a0H, Braak\u00a0E (1995) Staging of Alzheimers disease-related neurofibrillary changes. Neurobiol Aging 16(3):271\u20138","journal-title":"Neurobiol Aging"},{"key":"1210_CR5","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1001\/jamaneurol.2020.2526","volume":"77","author":"M Brendel","year":"2020","unstructured":"Brendel\u00a0M, Barthel\u00a0H, van Eimeren\u00a0T, Marek\u00a0K, Beyer\u00a0L, Song\u00a0M, Palleis\u00a0C, Gehmeyr\u00a0M, Fietzek\u00a0U, Respondek\u00a0G, Sauerbeck\u00a0J, Nitschmann\u00a0A, Zach\u00a0C, Hammes\u00a0J, Barbe\u00a0MT, Onur\u00a0O, Jessen\u00a0F, Saur\u00a0D, Schroeter\u00a0ML, Rumpf\u00a0J\u2011J, Rullmann\u00a0M, Schildan\u00a0A, Patt\u00a0M, Neumaier\u00a0B, Barret\u00a0O, Madonia\u00a0J, Russell\u00a0DS, Stephens\u00a0A, Roeber\u00a0S, Herms\u00a0J, B\u00f6tzel\u00a0K, Classen\u00a0J, Bartenstein\u00a0P, Villemagne\u00a0V, Levin\u00a0J, H\u00f6glinger\u00a0GU, Drzezga\u00a0A, Seibyl\u00a0J, Sabri\u00a0O (2020) Assessment of 18\u202fF-PI-2620 as a\u00a0biomarker in progressive supranuclear palsy. JAMA Neurol 77:1408. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2526","journal-title":"JAMA Neurol"},{"key":"1210_CR6","doi-asserted-by":"publisher","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","volume":"288","author":"A Crowe","year":"2013","unstructured":"Crowe\u00a0A, James\u00a0MJ, Lee\u00a0VM\u2011Y, Smith\u00a0AB, Trojanowski\u00a0JQ, Ballatore\u00a0C, Brunden\u00a0KR (2013) Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation. J\u00a0Biol Chem 288:11024\u201311037. https:\/\/doi.org\/10.1074\/jbc.M112.436006","journal-title":"J Biol Chem"},{"key":"1210_CR7","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos\u00a0SL, Miller\u00a0RL, Schoch\u00a0KM, Holmes\u00a0BB, Kebodeaux\u00a0CS, Wegener\u00a0AJ, Chen\u00a0G, Shen\u00a0T, Tran\u00a0H, Nichols\u00a0B, Zanardi\u00a0TA, Kordasiewicz\u00a0HB, Swayze\u00a0EE, Bennett\u00a0CF, Diamond\u00a0MI, Miller\u00a0TM (2017) Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med 9:eaag481. https:\/\/doi.org\/10.1126\/scitranslmed.aag0481","journal-title":"Sci Transl Med"},{"key":"1210_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2010.00136","author":"CJ Garwood","year":"2010","unstructured":"Garwood\u00a0CJ, Cooper\u00a0JD, Hanger\u00a0DP, Noble\u00a0W (2010) Anti-inflammatory impact of minocycline in a\u00a0mouse model of tauopathy. Front Psychiatry. https:\/\/doi.org\/10.3389\/fpsyt.2010.00136","journal-title":"Front Psychiatry"},{"key":"1210_CR9","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","volume":"388","author":"S Gauthier","year":"2016","unstructured":"Gauthier\u00a0S, Feldman\u00a0HH, Schneider\u00a0LS, Wilcock\u00a0GK, Frisoni\u00a0GB, Hardlund\u00a0JH, Moebius\u00a0HJ, Bentham\u00a0P, Kook\u00a0KA, Wischik\u00a0DJ, Schelter\u00a0BO, Davis\u00a0CS, Staff\u00a0RT, Bracoud\u00a0L, Shamsi\u00a0K, Storey\u00a0JMD, Harrington\u00a0CR, Wischik\u00a0CM (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a\u00a0randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388:2873\u20132884. https:\/\/doi.org\/10.1016\/S0140-6736(16)31275-2","journal-title":"Lancet"},{"key":"1210_CR10","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1093\/brain\/awm032","volume":"130","author":"LI Golbe","year":"2007","unstructured":"Golbe\u00a0LI, Ohman-Strickland\u00a0PA (2007) A clinical rating scale for progressive supranuclear palsy. Brain 130:1552\u20131565. https:\/\/doi.org\/10.1093\/brain\/awm032","journal-title":"Brain"},{"key":"1210_CR11","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13024-017-0181-0","volume":"12","author":"NB Hastings","year":"2017","unstructured":"Hastings\u00a0NB, Wang\u00a0X, Song\u00a0L, Butts\u00a0BD, Grotz\u00a0D, Hargreaves\u00a0R, Hess\u00a0FJ, Hong\u00a0K\u2011LK, Huang\u00a0CR\u2011R, Hyde\u00a0L, Laverty\u00a0M, Lee\u00a0J, Levitan\u00a0D, Lu\u00a0SX, Maguire\u00a0M, Mahadomrongkul\u00a0V, McEachern\u00a0EJ, Ouyang\u00a0X, Rosahl\u00a0TW, Selnick\u00a0H, Stanton\u00a0M, Terracina\u00a0G, Vocadlo\u00a0DJ, Wang\u00a0G, Duffy\u00a0JL, Parker\u00a0EM, Zhang\u00a0L (2017) Inhibition of O\u2011GlcNAcase leads to elevation of O\u2011GlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener 12:39. https:\/\/doi.org\/10.1186\/s13024-017-0181-0","journal-title":"Mol Neurodegener"},{"key":"1210_CR12","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1002\/mds.25815","volume":"29","author":"GU H\u00f6glinger","year":"2014","unstructured":"H\u00f6glinger\u00a0GU, Huppertz\u00a0H\u2011J, Wagenpfeil\u00a0S, Andr\u00e9s\u00a0MV, Belloch\u00a0V, Le\u00f3n\u00a0T, Del Ser\u00a0T, TAUROS MRI Investigators (2014) Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a\u00a0randomized trial. Mov Disord 29:479\u2013487. https:\/\/doi.org\/10.1002\/mds.25815","journal-title":"Mov Disord"},{"key":"1210_CR13","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00115-018-0584-3","volume":"89","author":"GG Kovacs","year":"2018","unstructured":"Kovacs\u00a0GG, Respondek\u00a0G, van Eimeren\u00a0T, H\u00f6ller\u00a0E, Levin\u00a0J, M\u00fcller\u00a0U, Schwarz\u00a0S, R\u00f6sler\u00a0TW, Schweyer\u00a0K, H\u00f6glinger\u00a0GU (2018) Tauopathien. Nervenarzt 89:1083\u20131094. https:\/\/doi.org\/10.1007\/s00115-018-0584-3","journal-title":"Nervenarzt"},{"key":"1210_CR14","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1016\/j.neurobiolaging.2011.11.009","volume":"33","author":"U Kr\u00fcger","year":"2012","unstructured":"Kr\u00fcger\u00a0U, Wang\u00a0Y, Kumar\u00a0S, Mandelkow\u00a0E\u2011M (2012) Autophagic degradation of tau in primary neurons and its enhancement by trehalose. Neurobiol Aging 33:2291\u20132305. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2011.11.009","journal-title":"Neurobiol Aging"},{"key":"1210_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.parkreldis.2020.08.021","volume":"79","author":"AE Lang","year":"2020","unstructured":"Lang\u00a0AE, Stebbins\u00a0GT, Wang\u00a0P, Jabbari\u00a0E, Lamb\u00a0R, Morris\u00a0H, Boxer\u00a0AL, Boxer\u00a0A, Boeve\u00a0B, Dickerson\u00a0B, Grossman\u00a0M, Litvan\u00a0I, Ljubenkov\u00a0P, Pantelyat\u00a0A, Rojas-Martinez\u00a0J, Tartaglia\u00a0M\u2011C, Wills\u00a0A\u2011M, Morris\u00a0H, Amar\u00a0K, Capps\u00a0E, Carey\u00a0G, Church\u00a0A, Critchley\u00a0P, Ghosh\u00a0B, Houlden\u00a0H, Hu\u00a0M, Jabbari\u00a0E, Kobylecki\u00a0C, Massey\u00a0L, Molloy\u00a0S, Nath\u00a0U, Pavese\u00a0N, Rowe\u00a0JB (2020) The cortical basal ganglia functional scale (CBFS): development and preliminary validation. Parkinsonism Relat Disord 79:121\u2013126. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.08.021","journal-title":"Parkinsonism Relat Disord"},{"key":"1210_CR16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.clineuro.2016.04.021","volume":"146","author":"L Leclair-Visonneau","year":"2016","unstructured":"Leclair-Visonneau\u00a0L, Rouaud\u00a0T, Debilly\u00a0B, Durif\u00a0F, Houeto\u00a0J\u2011L, Kreisler\u00a0A, Defebvre\u00a0L, Lamy\u00a0E, Volteau\u00a0C, Nguyen\u00a0J\u2011M, Le Dily\u00a0S, Damier\u00a0P, Boutoleau-Bretonni\u00e8re\u00a0C, Lejeune\u00a0P, Derkinderen\u00a0P (2016) Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosurg 146:35\u201339. https:\/\/doi.org\/10.1016\/j.clineuro.2016.04.021","journal-title":"Clin Neurol Neurosurg"},{"key":"1210_CR17","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.neuron.2018.10.031","volume":"100","author":"A Litvinchuk","year":"2018","unstructured":"Litvinchuk\u00a0A, Wan\u00a0Y\u2011W, Swartzlander\u00a0DB, Chen\u00a0F, Cole\u00a0A, Propson\u00a0NE, Wang\u00a0Q, Zhang\u00a0B, Liu\u00a0Z, Zheng\u00a0H (2018) Complement C3aR inactivation attenuates tau pathology and reverses an immune network deregulated in tauopathy models and Alzheimer\u2019s disease. Neuron 100:1337\u20131353.e5. https:\/\/doi.org\/10.1016\/j.neuron.2018.10.031","journal-title":"Neuron"},{"issue":"5","key":"1210_CR18","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/mds.28470","volume":"36","author":"M-T Gr\u00f6tsch","year":"2021","unstructured":"Gr\u00f6tsch\u00a0M\u2011T, Respondek\u00a0G, Colosimo\u00a0C, Compta\u00a0Y, Corvol\u00a0JC, Ferreira\u00a0J, Huber\u00a0MK, Klietz\u00a0M, Krey\u00a0LFM, Levin\u00a0J, Jecmenica-Lukic\u00a0M, Mac\u00edas-Garc\u00eda\u00a0D, Meissner\u00a0WG, Mir\u00a0P, Movement Disorder Society-Endorsed PSP Study Group (2021) A modified progressive supranuclear palsy rating scale. Mov Disord 36(5):1203\u20131215. https:\/\/doi.org\/10.1002\/mds.28470","journal-title":"Mov Disord"},{"key":"1210_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/FBP.0000000000000133","volume":"26","author":"V Melis","year":"2015","unstructured":"Melis\u00a0V, Magbagbeolu\u00a0M, Rickard\u00a0JE, Horsley\u00a0D, Davidson\u00a0K, Harrington\u00a0KA, Goatman\u00a0K, Goatman\u00a0EA, Deiana\u00a0S, Close\u00a0SP, Zabke\u00a0C, Stamer\u00a0K, Dietze\u00a0S, Schwab\u00a0K, Storey\u00a0JMD, Harrington\u00a0CR, Wischik\u00a0CM, Theuring\u00a0F, Riedel\u00a0G (2015) Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol 26:353\u2013368. https:\/\/doi.org\/10.1097\/FBP.0000000000000133","journal-title":"Behav Pharmacol"},{"key":"1210_CR20","doi-asserted-by":"publisher","first-page":"3680","DOI":"10.1523\/JNEUROSCI.2369-17.2018","volume":"38","author":"S-W Min","year":"2018","unstructured":"Min\u00a0S\u2011W, Sohn\u00a0PD, Li\u00a0Y, Devidze\u00a0N, Johnson\u00a0JR, Krogan\u00a0NJ, Masliah\u00a0E, Mok\u00a0S\u2011A, Gestwicki\u00a0JE, Gan\u00a0L (2018) SIRT1 deacetylates tau and reduces pathogenic tau spread in a\u00a0mouse model of tauopathy. J\u00a0Neurosci 38:3680\u20133688. https:\/\/doi.org\/10.1523\/JNEUROSCI.2369-17.2018","journal-title":"J Neurosci"},{"key":"1210_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/path.3969","volume":"226","author":"DA Nijholt","year":"2012","unstructured":"Nijholt\u00a0DA, van Haastert\u00a0ES, Rozemuller\u00a0AJ, Scheper\u00a0W, Hoozemans\u00a0JJ (2012) The unfolded protein response is associated with early tau pathology in the hippocampus of tauopathies. J\u00a0Pathol 226:693\u2013702. https:\/\/doi.org\/10.1002\/path.3969","journal-title":"J Pathol"},{"key":"1210_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1474-4422(16)30331-3","volume":"16","author":"P Novak","year":"2017","unstructured":"Novak\u00a0P, Schmidt\u00a0R, Kontsekova\u00a0E, Zilka\u00a0N, Kovacech\u00a0B, Skrabana\u00a0R, Vince-Kazmerova\u00a0Z, Katina\u00a0S, Fialova\u00a0L, Prcina\u00a0M, Parrak\u00a0V, Dal-Bianco\u00a0P, Brunner\u00a0M, Staffen\u00a0W, Rainer\u00a0M, Ondrus\u00a0M, Ropele\u00a0S, Smisek\u00a0M, Sivak\u00a0R, Winblad\u00a0B, Novak\u00a0M (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a\u00a0randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16:123\u2013134. https:\/\/doi.org\/10.1016\/S1474-4422(16)30331-3","journal-title":"Lancet Neurol"},{"key":"1210_CR23","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1002\/mds.27964","volume":"35","author":"I Piot","year":"2020","unstructured":"Piot\u00a0I, Schweyer\u00a0K, Respondek\u00a0G, Stamelou\u00a0M, Sckopke\u00a0P, Schenk\u00a0T, Goetz\u00a0CG, Stebbins\u00a0GT, H\u00f6glinger\u00a0GU, Gasser\u00a0T, Hermann\u00a0A, H\u00f6glinger\u00a0G, H\u00f6llerhage\u00a0M, Kimmich\u00a0O, Klockgether\u00a0T, Levin\u00a0J, Machetanz\u00a0G, Osterrath\u00a0A, Palleis\u00a0C, Prudlo\u00a0J, Spottke\u00a0A, Berg\u00a0D, B\u00fcrk\u00a0K, Cla\u00dfen\u00a0J, Eggers\u00a0C, Greuel\u00a0A, Grimm\u00a0M, Hermann\u00a0L, Iankova\u00a0V, Jahn\u00a0K, Jost\u00a0W, Klietz\u00a0M, K\u00fchn\u00a0A, Marxreiter\u00a0F, Paschen\u00a0S, Poetter-Nerger\u00a0M, Preisl\u00a0M, Prilop\u00a0L, T\u00f6nges\u00a0L, Trenkwalder\u00a0C, Warnecke\u00a0T, Wegner\u00a0F, Winkler\u00a0J, Antonini\u00a0A, Colosimo\u00a0C, Compta\u00a0Y, Corvol\u00a0J, Li\u00a0I, H\u00f6glinger\u00a0GU, Litvan\u00a0I, Nilsson\u00a0C, Pantelyat\u00a0A, Respondek\u00a0G, Stamelou\u00a0M (2020) The progressive Supranuclear palsy clinical deficits scale. Mov Disord 35:650\u2013661. https:\/\/doi.org\/10.1002\/mds.27964","journal-title":"Mov Disord"},{"key":"1210_CR24","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/acn3.290","volume":"3","author":"JC Rojas","year":"2016","unstructured":"Rojas\u00a0JC, Karydas\u00a0A, Bang\u00a0J, Tsai\u00a0RM, Blennow\u00a0K, Liman\u00a0V, Kramer\u00a0JH, Rosen\u00a0H, Miller\u00a0BL, Zetterberg\u00a0H, Boxer\u00a0AL (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216\u2013225. https:\/\/doi.org\/10.1002\/acn3.290","journal-title":"Ann Clin Transl Neurol"},{"key":"1210_CR25","doi-asserted-by":"publisher","first-page":"P251","DOI":"10.1016\/j.jalz.2018.06.2400","volume":"14","author":"JM Ryan","year":"2018","unstructured":"Ryan\u00a0JM, Quattropani\u00a0A, Abd-Elaziz\u00a0K, den Daas\u00a0I, Schneider\u00a0M, Ousson\u00a0S, Neny\u00a0M, Sand\u00a0A, Hantson\u00a0J, Permanne\u00a0B, Wiessner\u00a0C, Beher\u00a0D (2018) O1-12-05: phase 1 study in healthy volunteers of the O\u2011GlcNAcase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies. Alzheimers Dement 14:P251\u2013P251. https:\/\/doi.org\/10.1016\/j.jalz.2018.06.2400","journal-title":"Alzheimers Dement"},{"key":"1210_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00401-019-02080-2","volume":"139","author":"E Saijo","year":"2020","unstructured":"Saijo\u00a0E, Metrick\u00a0MA, Koga\u00a0S, Parchi\u00a0P, Litvan\u00a0I, Spina\u00a0S, Boxer\u00a0A, Rojas\u00a0JC, Galasko\u00a0D, Kraus\u00a0A, Rossi\u00a0M, Newell\u00a0K, Zanusso\u00a0G, Grinberg\u00a0LT, Seeley\u00a0WW, Ghetti\u00a0B, Dickson\u00a0DW, Caughey\u00a0B (2020) 4\u2011Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration. Acta Neuropathol 139:63\u201377. https:\/\/doi.org\/10.1007\/s00401-019-02080-2","journal-title":"Acta Neuropathol"},{"key":"1210_CR27","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1093\/brain\/aws143","volume":"135","author":"V Schaeffer","year":"2012","unstructured":"Schaeffer\u00a0V, Lavenir\u00a0I, Ozcelik\u00a0S, Tolnay\u00a0M, Winkler\u00a0DT, Goedert\u00a0M (2012) Stimulation of autophagy reduces neurodegeneration in a\u00a0mouse model of human tauopathy. Brain 135:2169\u20132177. https:\/\/doi.org\/10.1093\/brain\/aws143","journal-title":"Brain"},{"key":"1210_CR28","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.trsl.2017.11.004","volume":"193","author":"AW Schaler","year":"2018","unstructured":"Schaler\u00a0AW, Myeku\u00a0N (2018) Cilostazol, a\u00a0phosphodiesterase 3 inhibitor, activates proteasome-mediated proteolysis and attenuates tauopathy and cognitive decline. Transl Res 193:31\u201341. https:\/\/doi.org\/10.1016\/j.trsl.2017.11.004","journal-title":"Transl Res"},{"key":"1210_CR29","doi-asserted-by":"publisher","first-page":"10062","DOI":"10.1021\/acs.jmedchem.9b01090","volume":"62","author":"HG Selnick","year":"2019","unstructured":"Selnick\u00a0HG, Hess\u00a0JF, Tang\u00a0C, Liu\u00a0K, Schachter\u00a0JB, Ballard\u00a0JE, Marcus\u00a0J, Klein\u00a0DJ, Wang\u00a0X, Pearson\u00a0M, Savage\u00a0MJ, Kaul\u00a0R, Li\u00a0T\u2011S, Vocadlo\u00a0DJ, Zhou\u00a0Y, Zhu\u00a0Y, Mu\u00a0C, Wang\u00a0Y, Wei\u00a0Z, Bai\u00a0C, Duffy\u00a0JL, McEachern\u00a0EJ (2019) Discovery of MK-8719, a\u00a0potent O\u2011GlcNAcase inhibitor as a\u00a0potential treatment for tauopathies. J\u00a0Med Chem 62:10062\u201310097. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01090","journal-title":"J Med Chem"},{"key":"1210_CR30","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1586\/14737175.2016.1140039","volume":"16","author":"D Seripa","year":"2016","unstructured":"Seripa\u00a0D, Solfrizzi\u00a0V, Imbimbo\u00a0BP, Daniele\u00a0A, Santamato\u00a0A, Lozupone\u00a0M, Zuliani\u00a0G, Greco\u00a0A, Logroscino\u00a0G, Panza\u00a0F (2016) Tau-directed approaches for the treatment of Alzheimer\u2019s disease: focus on leuco-methylthioninium. Expert Rev Neurother 16:259\u2013277. https:\/\/doi.org\/10.1586\/14737175.2016.1140039","journal-title":"Expert Rev Neurother"},{"key":"1210_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.nbd.2011.12.050","volume":"46","author":"K Shimada","year":"2012","unstructured":"Shimada\u00a0K, Motoi\u00a0Y, Ishiguro\u00a0K, Kambe\u00a0T, Matsumoto\u00a0S\u2011E, Itaya\u00a0M, Kunichika\u00a0M, Mori\u00a0H, Shinohara\u00a0A, Chiba\u00a0M, Mizuno\u00a0Y, Ueno\u00a0T, Hattori\u00a0N (2012) Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion. Neurobiol Dis 46:101\u2013108. https:\/\/doi.org\/10.1016\/j.nbd.2011.12.050","journal-title":"Neurobiol Dis"},{"key":"1210_CR32","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/brain\/aww101","volume":"139","author":"HL Smith","year":"2016","unstructured":"Smith\u00a0HL, Mallucci\u00a0GR (2016) The unfolded protein response: mechanisms and therapy of neurodegeneration. Brain 139:2113\u20132121. https:\/\/doi.org\/10.1093\/brain\/aww101","journal-title":"Brain"},{"key":"1210_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/mds.22023","volume":"23","author":"M Stamelou","year":"2008","unstructured":"Stamelou\u00a0M, Reuss\u00a0A, Pilatus\u00a0U, Magerkurth\u00a0J, Niklowitz\u00a0P, Eggert\u00a0KM, Krisp\u00a0A, Menke\u00a0T, Schade-Brittinger\u00a0C, Oertel\u00a0WH, H\u00f6glinger\u00a0GU (2008) Short-term effects of coenzyme Q 10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord 23:942\u2013949. https:\/\/doi.org\/10.1002\/mds.22023","journal-title":"Mov Disord"},{"key":"1210_CR34","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1038\/mtna.2014.30","volume":"3","author":"R Sud","year":"2014","unstructured":"Sud\u00a0R, Geller\u00a0ET, Schellenberg\u00a0GD (2014) Antisense-mediated exon skipping decreases tau protein expression: a potential therapy for tauopathies. Mol Ther Nucleic Acids 3:e180. https:\/\/doi.org\/10.1038\/mtna.2014.30","journal-title":"Mol Ther Nucleic Acids"},{"key":"1210_CR35","doi-asserted-by":"publisher","first-page":"e72301","DOI":"10.1371\/journal.pone.0072301","volume":"8","author":"C Theunis","year":"2013","unstructured":"Theunis\u00a0C, Crespo-Biel\u00a0N, Gafner\u00a0V, Pihlgren\u00a0M, L\u00f3pez-Deber\u00a0MP, Reis\u00a0P, Hickman\u00a0DT, Adolfsson\u00a0O, Chuard\u00a0N, Ndao\u00a0DM, Borghgraef\u00a0P, Devijver\u00a0H, Van Leuven\u00a0F, Pfeifer\u00a0A, Muhs\u00a0A (2013) Efficacy and safety of a liposome-based vaccine against protein tau, assessed in Tau.P301L mice that model tauopathy. PLoS One 8:e72301. https:\/\/doi.org\/10.1371\/journal.pone.0072301","journal-title":"PLoS One"},{"key":"1210_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25824","author":"E Tolosa","year":"2014","unstructured":"Tolosa\u00a0E, Litvan\u00a0I, H\u00f6glinger\u00a0GU, Burn\u00a0D, Lees\u00a0A, Andr\u00e9s\u00a0MV, G\u00f3mez-Carrillo\u00a0B, Le\u00f3n\u00a0T, Del Ser\u00a0T, G\u00f3mez\u00a0JC, Tijero\u00a0B, Berganzo\u00a0K, Garc\u00eda de Yebenes\u00a0J, Lopez Send\u00f3n\u00a0JL, Garcia\u00a0G, Tolosa\u00a0E, Buongiorno\u00a0MT, Bargall\u00f3\u00a0N, Burguera\u00a0JA, Martinez\u00a0I, Ruiz-Mart\u00ednez\u00a0J, Narrativel\u00a0I, Vivancos\u00a0F, Ybot\u00a0I, Aguilar\u00a0M, Quilez\u00a0P, Boada\u00a0M, Lafuente\u00a0A, Hernandez\u00a0I, L\u00f3pez-Lozano\u00a0JJ, Mata\u00a0M, Kupsch\u00a0A, Lipp\u00a0A, Ebersbach\u00a0G, Schmidt\u00a0T, Hahn\u00a0K, H\u00f6glinger\u00a0G, H\u00f6llerhage\u00a0M, Oertel\u00a0WH, Respondek\u00a0G, Stamelou\u00a0M, Reichmann\u00a0H, Wolz\u00a0M, Schneider\u00a0C, Klingelh\u00f6fer\u00a0L, Berg\u00a0D, Maetzler\u00a0W, Srulijes\u00a0KK, Ludolph\u00a0A, Kassubek\u00a0J, Steiger\u00a0M, Tyler\u00a0K, Morris\u00a0L, Lees\u00a0A, Ling\u00a0H, Hauser\u00a0R, McClain\u00a0T, Truong\u00a0D, Jenkins\u00a0S, Litvan\u00a0I, Houghton\u00a0D, Ferrara\u00a0J, Bordelon\u00a0Y, Gratiano\u00a0A, Golbe\u00a0L, Mark\u00a0M, Uitti\u00a0R, Ven Gerpen\u00a0J (2014) A phase 2 trial of the GSK\u20113 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. https:\/\/doi.org\/10.1002\/mds.25824","journal-title":"Mov Disord"},{"key":"1210_CR37","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/mdc3.12940","volume":"7","author":"L VandeVrede","year":"2020","unstructured":"VandeVrede\u00a0L, Dale\u00a0ML, Fields\u00a0S, Frank\u00a0M, Hare\u00a0E, Heuer\u00a0HW, Keith\u00a0K, Koestler\u00a0M, Ljubenkov\u00a0PA, McDermott\u00a0D, Ohanesian\u00a0N, Richards\u00a0J, Rojas\u00a0JC, Thijssen\u00a0EH, Walsh\u00a0C, Wang\u00a0P, Wolf\u00a0A, Quinn\u00a0JF, Tsai\u00a0R, Boxer\u00a0AL (2020) Open-label phase 1 futility studies of salsalate and young plasma in progressive supranuclear palsy. Mov Disord Clin Pract 7:440\u2013447. https:\/\/doi.org\/10.1002\/mdc3.12940","journal-title":"Mov Disord Clin Pract"},{"key":"1210_CR38","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1038\/s41467-019-12070-3","volume":"10","author":"SM Waldherr","year":"2019","unstructured":"Waldherr\u00a0SM, Strovas\u00a0TJ, Vadset\u00a0TA, Liachko\u00a0NF, Kraemer\u00a0BC (2019) Constitutive XBP-1s-mediated activation of the endoplasmic reticulum unfolded protein response protects against pathological tau. Nat Commun 10:4443. https:\/\/doi.org\/10.1038\/s41467-019-12070-3","journal-title":"Nat Commun"},{"key":"1210_CR39","doi-asserted-by":"publisher","first-page":"102152","DOI":"10.1016\/j.nicl.2019.102152","volume":"25","author":"JL Whitwell","year":"2020","unstructured":"Whitwell\u00a0JL, Tosakulwong\u00a0N, Botha\u00a0H, Ali\u00a0F, Clark\u00a0HM, Duffy\u00a0JR, Utianski\u00a0RL, Stevens\u00a0CA, Weigand\u00a0SD, Schwarz\u00a0CG, Senjem\u00a0ML, Jack\u00a0CR, Lowe\u00a0VJ, Ahlskog\u00a0JE, Dickson\u00a0DW, Josephs\u00a0KA (2020) Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants. Neuroimage Clin 25:102152. https:\/\/doi.org\/10.1016\/j.nicl.2019.102152","journal-title":"Neuroimage Clin"},{"key":"1210_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/mds.27546","volume":"34","author":"JL Whitwell","year":"2019","unstructured":"Whitwell\u00a0JL, Tosakulwong\u00a0N, Schwarz\u00a0CG, Botha\u00a0H, Senjem\u00a0ML, Spychalla\u00a0AJ, Ahlskog\u00a0JE, Knopman\u00a0DS, Petersen\u00a0RC, Jack\u00a0CR, Lowe\u00a0VJ, Josephs\u00a0KA (2019) MRI outperforms [18F]AV-1451 PET as a\u00a0longitudinal biomarker in progressive supranuclear palsy. Mov Disord 34:105\u2013113. https:\/\/doi.org\/10.1002\/mds.27546","journal-title":"Mov Disord"},{"key":"1210_CR41","doi-asserted-by":"publisher","first-page":"e0224952","DOI":"10.1371\/journal.pone.0224952","volume":"15","author":"H Yadikar","year":"2020","unstructured":"Yadikar\u00a0H, Torres\u00a0I, Aiello\u00a0G, Kurup\u00a0M, Yang\u00a0Z, Lin\u00a0F, Kobeissy\u00a0F, Yost\u00a0R, Wang\u00a0KK (2020) Screening of tau protein kinase inhibitors in a\u00a0tauopathy-relevant cell-based model of tau hyperphosphorylation and oligomerization. PLoS ONE 15:e224952. https:\/\/doi.org\/10.1371\/journal.pone.0224952","journal-title":"PLoS ONE"},{"key":"1210_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nchembio.96","volume":"4","author":"SA Yuzwa","year":"2008","unstructured":"Yuzwa\u00a0SA, Macauley\u00a0MS, Heinonen\u00a0JE, Shan\u00a0X, Dennis\u00a0RJ, He\u00a0Y, Whitworth\u00a0GE, Stubbs\u00a0KA, McEachern\u00a0EJ, Davies\u00a0GJ, Vocadlo\u00a0DJ (2008) A potent mechanism-inspired O\u2011GlcNAcase inhibitor that blocks phosphorylation of tau in vivo. Nat Chem Biol 4:483\u2013490. https:\/\/doi.org\/10.1038\/nchembio.96","journal-title":"Nat Chem Biol"},{"key":"1210_CR43","doi-asserted-by":"publisher","first-page":"11213","DOI":"10.1073\/pnas.93.20.11213","volume":"93","author":"CM Wischik","year":"1996","unstructured":"Wischik\u00a0CM, Edwards\u00a0PC, Lai\u00a0RY, Roth\u00a0M, Harrington\u00a0CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93:11213\u201311218. https:\/\/doi.org\/10.1073\/pnas.93.20.11213","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"1210_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy297","author":"SH Yuan","year":"2018","unstructured":"Yuan\u00a0SH, Hiramatsu\u00a0N, Liu\u00a0Q, Sun\u00a0XV, Lenh\u00a0D, Chan\u00a0P, Chiang\u00a0K, Koo\u00a0EH, Kao\u00a0AS, Litvan\u00a0I, Lin\u00a0JH (2018) Tauopathy-associated PERK alleles are functional hypomorphs that increase neuronal vulnerability to ER stress. Hum Mol Genet. https:\/\/doi.org\/10.1093\/hmg\/ddy297","journal-title":"Hum Mol Genet"},{"key":"1210_CR45","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1474-4422(20)30489-0","volume":"20","author":"GU H\u00f6glinger","year":"2021","unstructured":"H\u00f6glinger\u00a0GU, Litvan\u00a0I, Mendonca\u00a0N et al (2021) Safety and efficacy of tilavonemab in progressive supranuclear palsy: a\u00a0phase 2, randomised, placebo-controlled trial. Lancet Neurol 20:182\u2013192. https:\/\/doi.org\/10.1016\/S1474-4422(20)30489-0","journal-title":"Lancet Neurol"},{"key":"1210_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30157-6","author":"J-T Yu","year":"2017","unstructured":"Yu\u00a0J\u2011T, Lang\u00a0AE, Boxer\u00a0AL, Yu\u00a0J\u2011T, Golbe\u00a0LI, Litvan\u00a0I, Lang\u00a0AE, H\u00f6glinger\u00a0GU (2017) Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. https:\/\/doi.org\/10.1016\/S1474-4422(17)30157-6","journal-title":"Lancet Neurol"},{"key":"1210_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"91","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg\u00a0H (2016) Neurofilament light: a dynamic cross-disease fluid biomarker for neurodegeneration. Neuron 91:1\u20133. https:\/\/doi.org\/10.1016\/j.neuron.2016.06.030","journal-title":"Neuron"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-021-01210-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-021-01210-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T19:12:37Z","timestamp":1638817957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-021-01210-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":47,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1210"],"URL":"https:\/\/doi.org\/10.1007\/s00115-021-01210-0","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"value":"0028-2804","type":"print"},{"value":"1433-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"20 September 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Respondek hat eine bezahlte Beratert\u00e4tigkeit bei UCB Pharma ausge\u00fcbt. H.\u00a0Pflugrad hat Honorar f\u00fcr ein Interview von Merz Pharmaceuticals GmbH erhalten. G.U.\u00a0H\u00f6glinger \u00fcbt eine bezahlte Beratert\u00e4tigkeit f\u00fcr Abbvie, Alzprotect, Asceneuron, Bial, Biogen, Biohaven, Kyowa Kirin, Lundbeck, Novartis, Retrotope, Roche, Sanofi, UCB aus und erhielt Honorar f\u00fcr einen wissenschaftlichen Vortrag von Abbvie, Bayer Vital, Bial, Biogen, Bristol Myers Squibb, Kyowa Kirin, Roche, Teva, UCB, Zambon. L.\u00a0Krey, M.\u00a0Huber und F.\u00a0Wegner geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}